DBV Technologies SA Sponsored ADR

DBV Technologies SA is a clinical-stage biopharmaceutical company, which engages in the research and development of epicutaneous immunotherapy products. The firm focuses on the development of Viaskin, an electrostatic patch, which may offer a convenient, self-administered, and non-invasive immunotherapy to patients. It also designs a robust clinical development program that includes ongoing clinical trials of Viaskin peanut, and Viaskin milk, as well as pre-clinical development of Viaskin egg. The company was founded by Pierre-Henri Benhamou, Stéphane Benhamou, Bertrand Dupont, Christophe Dupont, and Pierre-Yves Vannerom on March 29, 2002 and is headquartered in Montrouge, France.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

DBV Technologies to Participate in an Upcoming Investor Conference

DBV Technologies S.A. (DBVT) is technically in oversold territory now, so the heavy selling pressure might have exhausted.

Down 42.6% in 4 Weeks, Here's Why You Should You Buy the Dip in DBV Technologies S.A. (DBVT)

The company plans to announce new data for its experimental peanut allergy drug this week.

Why DBV Technologies Stock Is Jumping Today

Down 36.6% in 4 Weeks, Here's Why You Should You Buy the Dip in DBV Technologies S.A. (DBVT)

DBV Technologies to Highlight New Long-term Data from REALISE Trial at ACAAI 2021

DBV Technologies (NASDAQ: DBVT) has received communication from the FDA concerning the STAMP protocol submission for its modified Viaskin Peanut (mVP) development program. The agency would like to review DBV's protein uptake release study data before providing additional comments on the STAMP protocol design.

DBV Technologies Shares Down On FDA Update For Its Peanut Allergy Program

DBV Technologies Reports Third Quarter 2021 Financial Results and Recent Regulatory Developments

DBV Technologies to Participate at Upcoming Investor Conferences

DBV Technologies S.A. (DBVT) CEO Daniel Tassé on Q2 2021 Results - Earnings Call Transcript

DBV Technologies Reports Second Quarter 2021 Financial Results and Recent Business Developments

DBV Technologies to Report First Half 2021 Financial Results and Business Updates on August 2, 2021

DBV Technologies Announces Results of its 2021 Ordinary and Extraordinary General Meeting and the Appointment of Dr. Adora Ndu, Pharm.D., J.D., and Dr. Ravi Madduri Rao, M.D.

DBV Technologies Announces Filing of its First Form 10-Q for the First Quarter of 2021

DBV Technologies Reports Q1 2021 Financial Results

Ordinary and Extraordinary General Meeting of May 19, 2021 to be Held in Closed Virtual Session Due to COVID-19 Pandemic

Montrouge, France, April 2, 2021 DBV Technologies Announces Appointment of Timothy E. Morris to Board of Directors

DBV Technologies Announces Appointment of Timothy E. Morris to Board of Directors

Monthly information regarding the total number of voting rights and

Monthly information regarding the total number of voting rights and total number of shares of the Company as of March 31, 2021

DBV Technologies Announces a New Chair of its Audit Committee and Date of its Annual General Meeting

DBV Technologies Announces Filing of 2020 Annual Report on Form 10-K and 2020 Universal Registration Document

Monthly information regarding the total number of voting rights and total number of shares of the Company as of February 28, 2021

The company released its latest quarterly update, and investors liked what they saw.

Why DBV Technologies Stock Is Rising Today

The stock price of DBV Technologies (NASDAQ: DBVT) has increased by over 10% pre-market. This is why it happened.

DBVT Stock Price Increases Over 10% Pre-Market: Why It Happened

DBV Technologies S.A. (DBVT) CEO Daniel Tassé on Q4 2020 Results - Earnings Call Transcript

DBV Technologies Reports Full-Year 2020 Financial Results and Recent Business Developments

DBV Technologies to Participate in the H.C. Wainwright Global Life Sciences Conference

News for DBV Technologies SA Sponsored ADR Stock (DBVT)